Article
A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations.
Integrative cancer therapies - 1 Jan 2000
Kwag Eunbin, Kim Soo-Dam, Shin Seong-Hoon, Oak Chulho, Park So-Jung, Choi Jun-Yong, Hoon Yoon Seong, Kang In-Cheol, Jeong Mi-Kyung, Woo Lee Hyun, Bang Sun-Hwi, Son Ji Woong, Lee Sanghun, Kim Seung Joon, Yoo Hwa-Seung
Abstract excerpt
BACKGROUND: Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has shown superior efficacy over traditional chemotherapy in NSCLC treatment. However, issues like secondary resistance and adverse effects call for alternative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.